Back
Novavax 10K Form
Sell
25
NVAX
Novavax
Last Price:
7.33
Seasonality Move:
16.27%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-10 | 10Q | NVAX/Novavax Quarterly |
| 2024-02-28 | 10K | NVAX/Novavax Annual |
| 2023-11-09 | 10Q | NVAX/Novavax Quarterly |
| 2023-08-08 | 10Q | NVAX/Novavax Quarterly |
| 2023-05-09 | 10Q | NVAX/Novavax Quarterly |
| 2023-02-28 | 10K | NVAX/Novavax Annual |
Receive NVAX News And Ratings
See the #1 stock for the next 7 days that we like better than NVAX
NVAX Financial Statistics
Sales & Book Value
| Annual Sales: | $556.38M |
|---|---|
| Cash Flow: | $311.14M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-2.70 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -2.79000 |
|---|---|
| Net Income (TTM): | $-294.33M |
| Gross Margin: | $212.61M |
| Return on Equity: | 0% |
| Return on Assets: | -17.71% |
Novavax Earnings Forecast
Key Novavax Financial Ratios
- The Gross Profit Margin over the past 25 years for NVAX is 38.21%.
- The Selling, General & Administrative Expenses for NVAX have been equal to 84.28% of Gross Profit Margin.
- The Research & Development expenses have been 132.55% of Revenue.
- The Interest Expense is -2.64% of Operating Income.
- The Net Earning history of NVAX is -97.97% of Total Revenues.
- Per Share Earnings over the last 28 years have been positive in 13 years.
Novavax Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NVAX |
| CUSIP: | 670002 |
| Website: | novavax.com |
Debt
| Debt-to-Equity Ratio: | -0.39 |
|---|---|
| Current Ratio: | 1.04 |
| Quick Ratio: | 0.93 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 7.42 |